Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + S-1/Capecitabine in 2L Advanced Pancreatic Cancer
NCT06532617Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Shanghai General Hospital. Primary endpoint: Objective Response Rate at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
cadonilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06532617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532617.